ArticleJournal of cancer survivorship : research and practice2024
Survivorship science at the National Institutes of Health 2017-2021.
Article in Journal of cancer survivorship : research and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- How prevalent is fear of cancer recurrence beyond 5 years: a systematic review of validated assessments across tumour types.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Disparities in healthcare utilization and access by measures of economic stability among female cancer survivors in Maryland.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Comparing National Institutes of Health funding for cancer survivorship: a spotlight on breast and gynecologic cancer.American journal of obstetrics and gynecology · 2026Article
- Symptom Clusters and Symptom Burden in Cancer Survivors.Cancer medicine · 2026Article
- Re-examining survivorship research for people living with advanced and metastatic cancers: A portfolio analysis update of National Institutes of Health-funded grants.Journal of cancer survivorship : research and practice · 2025Article
- Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions.Medical oncology (Northwood, London, England) · 2025Review
- Therapy-Related-Myeloid-Neoplasm-Risk Score: a convenient score for therapy-related myeloid neoplasms risk assessment in adult cancer patients.JNCI cancer spectrum · 2025Article
- Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023.Cancer causes & control : CCC · 2025Article
- NCI-Funded Cancer Epidemiology Survivor Cohorts: Overview, Progress, and Opportunities.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Prevalence of cancer survivors diagnosed during adolescence and young adulthood in the United States.Journal of the National Cancer Institute · 2025Article
- Prevalence of cancer survivors in the United States.Journal of the National Cancer Institute · 2024Article
- Disparities in cancer clinical trials information-seeking: Findings from the National Cancer Institute's Cancer Information Service.Patient education and counseling · 2024Article
- Advancing health equity in cancer survivorship research: National Institutes of Health 2017-2022 portfolio review.Journal of the National Cancer Institute · 2024Article
- Re-visiting the call for translation of cancer survivorship research: collaborative multidisciplinary approaches to improve translation and dissemination.Cancer causes & control : CCC · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the characteristics of National Institutes of Health (NIH) cancer survivorship grants funded over the past 5 years and identify gap areas for future efforts and initiatives.
methodsResearch project grants (RPG) funded during Fiscal Year (FY) 2017 to 2021 focused on cancer survivorship were identified using a text mining algorithm of words from the NIH Research, Condition, and Disease Categorization (RCDC) thesaurus with survivorship-relevant terms. The title, abstract, specific aims, and public health relevance section of each grant were reviewed for eligibility. Grants meeting the eligibility criteria were double coded to extract study characteristics (e.g., grant mechanism, study design, study population).
resultsA total of 586 grants were funded by 14 NIH Institutes from FY2017 to FY2021, and the number of newly funded grants increased each FY, from 68 in 2017 to 105 in 2021. Approximately 60% of all grants included an intervention study, and interventions most often focused on psychosocial or supportive care (32.0%). The most common primary focus of the grants was late- and long-term effects of cancer treatment (46.6%), and least often financial hardship.
conclusionsThe results of this portfolio analysis indicate overall growth in the number and breadth of grants over the last five years, although notable gaps persist. IMPLICATIONS FOR CANCER SURVIVORS: This review of current NIH grants suggests a need for expanded research to understand and address survivor needs to ensure that the over 18 million cancer survivors in the United States have optimal quality of life and health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.